Quantcast

Latest Monoclonal antibodies Stories

2014-07-22 12:27:43

Genzyme/Sanofi's Lemtrada and Genentech/Roche's Ocrelizumab Will Likely Be Reserved for Patients with Aggressive/Severe MS, According to Findings from Decision Resources Group BURLINGTON, Mass., July 22, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of audited multiple sclerosis (MS) patients currently treated with Biogen Idec's oral disease-modify therapy (DMT) Tecfidera have ever experienced flushing and/or gastrointestinal events while on the therapy. However, few...

2014-07-21 08:30:52

LONDON, July 21, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global Antibody Drug Conjugate Market Outlook 2018https://www.reportbuyer.com/product/2048454/Global-Antibody-Drug-Conjugate-Market-Outlook-2018.html The ADC technology is not new. It dates back to the 90s. However, several issues such as specificity of the payload (drug), and poor conjugation of drug and antibody proved a setback. But, the past few years have witnessed ADCs make a glorious...

2014-07-17 08:29:29

Nearly half a million dollars given to early-career physicians to study psoriatic disease PORTLAND, Ore., July 17, 2014 /PRNewswire-USNewswire/ -- Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis and psoriatic arthritis as...

2014-07-15 08:28:23

MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors. Mr. Gustafson will also serve as chair of Xencor's audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R....

2014-07-13 23:01:22

The increasing number of research activities, coupled with the introduction of advanced technologies in chromatography instruments and consumables, will drive the growth of chromatography systems market. http://www.micromarketmonitor.com/market/north-america-chromatography-systems-3162983548.html (PRWEB) July 13, 2014 Chromatography system is a physical method of separation of biological components from various types of biological samples such as air and water. Chromatography systems...

2014-07-10 12:30:51

ST. PETERSBURG, Russia, July 10, 2014 /PRNewswire/ -- On July 9 Prime Minister of the Russian Federation Dmitry Medvedev, presented Russia's first national "Industry" award to a biopharmaceutical company BIOCAD [http://biocad.ru/en ]. The Company is developing a unique project called MabNext [http://biocad.ru/en/science ]. Within the scope of MabNext project BIOCAD develops a number of innovative drugs based on monoclonal antibodies for treatment of cancer and autoimmune...

2014-07-07 16:02:23

European League Against Rheumatism Low dosing of infliximab does not appear to alter treatment response or adherence Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit. Further data revealed that, in the case of the TNFα inhibitor...

First Antibodies To Treat Cancer In Dogs Developed
2014-07-07 03:10:21

University of Veterinary Medicine Vienna Nearly every second dog develops cancer from the age of ten years onward. A few therapies derived from human medicine are available for dogs. A very successful form of therapy by which antibodies inhibit tumor growth has not been available for animals so far. Scientists at the inter-university Messerli Research Institute of the Vetmeduni Vienna, the Medical University of Vienna, and the University of Vienna have developed, for the first time,...

2014-07-03 23:03:22

High demand for chromatography reagents in the pharmaceutical industry and innovation in chromatography reagents market will propel the global size exclusion chromatography reagents market. http://www.micromarketmonitor.com/market-report/global-size-exclusion-chromatography-reagents-reports-4179419567.html (PRWEB) July 03, 2014 The global size exclusion chromatography reagents market was $812 million in 2013, and is expected to reach $1302 million by 2018, at a CAGR of 9.9%. Rise in...

2014-07-03 08:23:49

MUMBAI,India, July 3, 2014 /PRNewswire/ -- - GBR 830 is an antagonistic monoclonal antibody with first in class potential for the treatment of autoimmune diseases targeting OX40, a co-stimulatory receptor on T cells - The antibody has successfully completed the Phase I enabling preclinical development program and a Phase I clinical trial application has been filed with The Netherlands authorities -...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related